New drug cocktail shows promise for tough bile duct cancer
NCT ID NCT04781192
First seen Jan 26, 2026 · Last updated May 19, 2026 · Updated 15 times
Summary
This study tests whether combining two drugs, regorafenib and durvalumab, can help people with advanced biliary tract cancer that has stopped responding to chemotherapy. About 40 participants will receive the treatment to see if it shrinks tumors or slows disease progression. The main goals are to check safety and how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The University of Kansas Medical Center
Westwood, Kansas, 66205, United States
-
The University of Kansas Medical Center
North Kansas City, Missouri, 64116, United States
-
University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri, 64064, United States
-
University of Kansas Cancer Center - North
Kansas City, Missouri, 64154, United States
-
University of Kansas Cancer Center - Overland Park
Overland Park, Kansas, 66210, United States
Conditions
Explore the condition pages connected to this study.